Profound Medical Corp. develops AI-powered, MRI-guided robotic systems for incision-free thermal ablation of diseased tissue. The TULSA-PRO system uses transurethral ultrasound with real-time MRI imaging and closed-loop temperature control to treat prostate conditions while seeking to preserve patients' urinary and sexual function. It also markets the Sonalleve platform for the treatment of uterine fibroids and palliative care of bone metastases.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 2.6 | — | -10.7 | — |
| Q2 2025 | 2.2 | — | -15.7 | — |
| Q3 2025 | 5.3 | — | -8 | — |
| Q4 2025 | 6 | — | -8.2 | — |
| Q1 2026 | 5.3 | 103.6% | -7 | — |
| Q2 2026 | 2.5 | 12.3% | -9.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: BNB Standard Corporation (BNC), Lifetime Brands, Inc. (LCUT), Compugen Ltd. (CGEN), Patriot Acquisition Corp. (PTAC), QumulusAI, Inc. (QMLS), Velo3D, Inc. (VELO)